If You Invested in Koru Med Sys (KRMD)

KORU Medical Systems, Inc. (NASDAQ: KRMD) is a medical technology company in the surgical and medical instrument manufacturing industry. The company focuses on the development, manufacturing, and commercialization of large-volume subcutaneous infusion solutions designed to be patient-centric and to improve quality of life for patients around the world. According to multiple company disclosures, KORU Medical’s core offering is the Freedom Syringe Infusion System (the “Freedom System”), a mechanical subcutaneous infusion platform used in home and clinical settings.

Core products and Freedom Infusion System

The Freedom System is described in company materials as a syringe infusion system that enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. It supports drug products with various requirements for viscosity, flow rate, and delivered drug volume. The Freedom System currently includes:

• Freedom60® Syringe Infusion Driver
• FreedomEdge® Syringe Infusion Driver
• Precision Flow Rate Tubing™
• HIgH-Flo / High-Flo Subcutaneous Safety Needle Sets™

Company disclosures note that the Freedom System received its first U.S. Food and Drug Administration (FDA) 510(k) clearance in 1994. It is used for self-administration in the home by patients and for drug delivery in ambulatory infusion centers or other clinical settings by healthcare professionals. KORU Medical also states that its Freedom infusion pumps were the first devices to be 510(k) cleared for use with prefilled syringes in subcutaneous immunoglobulin (SCIg) therapy.

Therapeutic areas and use cases

Based on company descriptions and prior summaries, KORU Medical’s subcutaneous infusion devices are used to deliver large-volume subcutaneous drugs, including immunoglobulin therapies for chronic illnesses such as primary immunodeficiencies (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company highlights its role in SCIg therapy and has reported a development agreement focused on next-generation infusion systems in subcutaneous immunoglobulin therapy for both commercial drugs and clinical programs.

KORU Medical has also disclosed initiatives to expand the use of its technology into additional therapeutic areas. The company has submitted a 510(k) premarket notification seeking clearance for the use of the FreedomEdge® infusion system to subcutaneously administer PHESGO® (pertuzumab/trastuzumab/hyaluronidase-zzxf), a co-formulated therapy for HER2+ breast cancer. In addition, KORU Medical has announced collaboration with ForCast Orthopedics, where the FreedomEdge pump will provide infusion technology as part of a wearable intra-articular infusion system for the treatment of periprosthetic joint infection.

Business model and segments

Company disclosures describe KORU Medical as both a developer and manufacturer of medical devices and supplies. Revenue is generated from the sale of its Freedom System hardware and related consumables, as well as from services to biopharmaceutical partners. KORU Medical reports:

• A core business that includes domestic and international sales of pumps and consumables used in subcutaneous drug delivery.
• A Pharma Services and Clinical Trials (also referred to as Pharma Services and Clinical Trials or Novel Therapies) business that provides products for use by biopharmaceutical companies in feasibility and clinical trials during the drug development process.

Through this pharma-focused business, the company states that it can customize the Freedom System for clinical and commercial use across multiple drug categories, supporting biopharmaceutical partners as they develop and commercialize subcutaneous therapies.

Manufacturing and supply relationships

KORU Medical reports that it manufactures and commercializes its infusion systems and has entered into manufacturing and supply agreements to support production. An Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. covers the manufacture and supply of subassemblies, needle sets, and tubing products according to KORU Medical’s specifications and purchase orders. The agreement includes terms related to pricing, payment, quality management, business continuity plans, and other customary provisions for medical device manufacturing relationships.

Clinical and real-world experience

Across multiple press releases, KORU Medical cites extensive real-world use of the Freedom System. The company reports that the system has been used for patient self-administration in the home for more than 15 years, supporting tens of thousands of patients and millions of infusions annually, with distribution across numerous countries. Company materials also refer to a high adherence rate for patients using the Freedom System and multiple on-label subcutaneous drugs supported by the platform.

KORU Medical has sponsored and presented research evaluating its infusion systems in clinical practice. One multicenter evaluation across hospitals in Denmark compared the FreedomEdge® Infusion System with traditional manual push techniques for short-duration subcutaneous infusions in oncology and immunology settings. Reported results included high nurse satisfaction, favorable workflow efficiency, and positive patient experience metrics. These findings are used by the company to illustrate how mechanical subcutaneous infusion can affect nursing workflow and patient comfort in infusion centers.

Regulatory and quality focus

The company’s disclosures emphasize its engagement with regulatory pathways such as FDA 510(k) clearances for specific drugs and indications. The Freedom System’s initial clearance in 1994 and subsequent submissions for additional drugs, including rare disease biologics and oncology biologics, reflect an ongoing focus on regulatory alignment between the device platform and partner drug products. KORU Medical also highlights quality management and inspection procedures in its manufacturing and supply agreements, underscoring the importance of consistent product performance for subcutaneous drug delivery.

Partnerships and pharma collaborations

KORU Medical positions its infusion technology as a platform for collaboration with biopharmaceutical companies. Through its Pharma Services and Clinical Trials business, the company provides Freedom System devices and related components for feasibility and clinical trials, and it notes that it can adapt the system for different drug characteristics, including viscosity, flow rate, and volume requirements. The development agreement with a global pharmaceutical company for next-generation SCIg infusion systems, and the collaboration with ForCast Orthopedics on antibiotic infusion for periprosthetic joint infection, illustrate how KORU Medical’s technology can be integrated into broader therapeutic platforms.

Stock listing and regulatory filings

KORU Medical Systems, Inc. states in its SEC filings that its common stock trades on The Nasdaq Stock Market under the symbol "KRMD". The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K, which provide additional detail on its operations, financial condition, risk factors, and material agreements. Recent Form 8-K filings have covered financial results, updated guidance, and material agreements such as the amended manufacturing and supply contract.

Position within medical device and drug delivery markets

Within the broader manufacturing sector, KORU Medical is classified in the surgical and medical instrument manufacturing industry. Its disclosures consistently describe a focus on large-volume subcutaneous drug delivery, particularly in immunology, rare disease, and oncology settings. By concentrating on mechanical syringe infusion systems and related consumables, the company aims to support home-based therapy and infusion-center workflows for subcutaneous treatments that might otherwise require more resource-intensive administration methods.

Evergreen considerations for investors and observers

For those researching KRMD stock, key structural aspects of KORU Medical’s business, based on company and regulatory disclosures, include:

• A device platform centered on the Freedom60® and FreedomEdge® syringe infusion drivers and associated tubing and needle sets.
• Use of the Freedom System for home self-administration and clinical delivery of large-volume subcutaneous drugs, including immunoglobulin therapies.
• A business model that combines core product sales with pharma services and clinical trial support, including customization of the device platform for different drugs.
• Ongoing regulatory interactions through FDA 510(k) submissions for specific biologics and indications.
• Collaborations with pharmaceutical and medical technology partners in areas such as SCIg therapy, oncology biologics, and targeted antibiotic delivery.

These elements, drawn from company press releases and SEC filings, describe the enduring features of KORU Medical’s operations and technology platform, independent of short-term financial results.